Yoram A. Puius

Yoram A. Puius

Auto-generated profile, based on publicly available information

Yoram A. Puius

Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2018 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
AKAllison Kutner
Allison Kutner
MAMargaret Aldrich
Margaret Aldrich
SPSarju Patel
Sarju Patel
JKJoann J. Kang
Joann J. Kang
BABijal Amin
Bijal Amin
YPYoram A. Puius
Yoram A. Puius

25 November 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
VHVagish Hemmige
Vagish Hemmige
OSOmar Saeed
Omar Saeed
YPYoram A. Puius
Yoram A. Puius
YAYorg Azzi
Yorg Azzi
ACAdriana Colovai
Adriana Colovai
SPSnehal Patel
Snehal Patel

1 January 2021 in Emerging Infectious Diseases
Verified
Journal Article
Open access
SAShitij Arora
Shitij Arora
VHVagish S. Hemmige
Vagish S. Hemmige
CMCharuta Mandke
Charuta Mandke
MCMayank Chansoria
Mayank Chansoria
SRSumit Kumar Rawat
Sumit Kumar Rawat
YPYoram A. Puius
Yoram A. Puius
Online Registry of COVID-19–Associated Mucormycosis Cases, India, 2021

1 February 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
YPYoram A Puius
Yoram A Puius
Marwan M. AzarMarwan M. Azar
Marwan M. Azar
HTHelen Tsai
Helen Tsai
Paschalis VergidisPaschalis Vergidis
Paschalis Vergidis
CHCourtney Harris
Courtney Harris
NSNeeraja Swaminathan
Neeraja Swaminathan
The field of transplant infectious diseases is rapidly evolving, presenting a challenge for clinical practice and trainee education. Here we describe the construction of transplantid.net, a free online library, crowdsourced and continuously updated for the dual purpose of point-of-care evidence-based management and teaching.

12 November 2020 in ASAIO Journal
Verified
Journal Article
Closed access
YPYoram A. Puius
Yoram A. Puius
FPFauziya Parkar
Fauziya Parkar
ATAileen P. Tlamsa
Aileen P. Tlamsa
JNJustin A. Nistico
Justin A. Nistico
VMVictoria A. Muggia
Victoria A. Muggia
RMRenée M. Moadel
Renée M. Moadel
Our institution employs gallium-67 single-photon emission computed tomography low-dose CT (Ga-SPECT-CT) to determine the presence and extent of left ventricular assist device (LVAD) infections. We present a retrospective single-center study of 41 LVAD recipients who underwent Ga-SPECT-CT from January 2011 to June 2018 to determine whether Ga-SPECT-CT led to changes in antimicrobial therapy, LVAD revision or exchange, or application for 1A exception. The average age was 56.6 years, predominantly male (80.5%) and diabetic (68.3%), divided between ischemic (48.8%) and nonischemic (51.2%) cardiomyopathy. The majority had HeartMate II devices (82.9%). Device-related infections were classified as possible (12.2%), probable (36.6%), proven (36.6%), or rejected (14.6%). Sensitivity was 68.6% and specificity was 100%. Most VAD-specific infections were percutaneous deep driveline infections (DRIs) (34.1%), and VAD-related infections were primarily bloodstream infections (31.7%). Staphylococcus aureus was the major pathogen isolated. Gallium-67 single-photon emission computed tomography low-dose CT resulted in changes in management in more than half (53.7%) of patients: starting (24.4%) or stopping (17.1%) antimicrobial therapy, LVAD revision (22.0%) or exchange (12.2%), and the application for 1A exception for transplant listing (17.1%). We conclude that Ga-SPECT-CT is an effective modality for determining the presence and extent of LVAD DRIs, and contributed to a change in management in more than half of cases.

1 November 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
MCMiguel E. Cervera-Hernandez
Miguel E. Cervera-Hernandez
WSWendy Szymczak
Wendy Szymczak
YPYoram A. Puius
Yoram A. Puius
JSJonathan Shuter
Jonathan Shuter